Exacerbated Inflammatory Gene Expression After Impaired G2/M-Checkpoint Arrest in Fibroblasts Derived From a Patient Exhibiting Severe Adverse Effects.


Journal

Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 31 10 2023
accepted: 25 04 2024
medline: 12 7 2024
pubmed: 12 7 2024
entrez: 12 7 2024
Statut: epublish

Résumé

Recent radiation therapy (RT), such as intensity modulated radiation therapy and particle RT, has improved the concentration of the radiation field targeting tumors. However, severe adverse effects still occur, possibly due to genetic factors in patients. We aimed to investigate the mechanism of exacerbated inflammation during RT. Dermal fibroblasts derived from a patient with severe inflammatory adverse effects during RT were compared with 2 normal human dermal fibroblasts. Micronuclei formation, G2/M-checkpoint arrest, DNA damage signaling and repair, and inflammatory gene expression were comprehensively examined. We found greater micronuclei formation in radiation-sensitive fibroblasts (RS-Fs) after ionizing radiation (IR). RS-Fs exhibited premature G2/M-checkpoint release after IR, which triggers micronuclei formation because RS-Fs undergo mitosis with unrepaired DNA double-strand breaks (DSBs). Additionally, we found that DSB end-resection and activation of the ATR-Chk1 pathway were impaired in RS-Fs after IR. Consistent with the increase in the formation of micronuclei, which can deliver cytosolic nucleic acids resulting in an innate immune response, the expression of genes associated with inflammatory responses was highly upregulated in RS-Fs after IR. Although this is a single case of RT-dependent adverse effect, our findings suggest that impaired G2/M-checkpoint arrest due to the lack of DSB end-resection and activation of the ATR-Chk1 pathway causes exacerbated inflammation during RT; therefore, genes involved in G2/M-checkpoint arrest may be a predictive marker for unexpected inflammatory responses in RT.

Identifiants

pubmed: 38993194
doi: 10.1016/j.adro.2024.101530
pii: S2452-1094(24)00093-9
pmc: PMC11238256
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101530

Informations de copyright

© 2024 Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Takahiro Oike (T)

Department of Radiation Oncology, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma, Japan.
Gunma University Heavy Ion Medical Center, Showa-machi, Maebashi, Gunma, Japan.

Ken Okuda (K)

Division of Molecular Oncological Pharmacy, Shibakoen, Minato-ku, Tokyo, Japan.

Shunji Haruna (S)

Division of Molecular Oncological Pharmacy, Shibakoen, Minato-ku, Tokyo, Japan.

Akiko Shibata (A)

Gunma University Heavy Ion Medical Center, Showa-machi, Maebashi, Gunma, Japan.

Ryota Hayashi (R)

Division of Molecular Oncological Pharmacy, Shibakoen, Minato-ku, Tokyo, Japan.

Mayu Isono (M)

Division of Molecular Oncological Pharmacy, Shibakoen, Minato-ku, Tokyo, Japan.

Kohei Tateno (K)

Division of Molecular Oncological Pharmacy, Shibakoen, Minato-ku, Tokyo, Japan.
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Showa-machi, Maebashi, Japan.

Nobuteru Kubo (N)

Department of Radiation Oncology, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma, Japan.
Gunma University Heavy Ion Medical Center, Showa-machi, Maebashi, Gunma, Japan.

Akihiko Uchiyama (A)

Department of Dermatology, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma, Japan.

Sei-Ichiro Motegi (SI)

Department of Dermatology, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma, Japan.

Tatsuya Ohno (T)

Department of Radiation Oncology, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma, Japan.
Gunma University Heavy Ion Medical Center, Showa-machi, Maebashi, Gunma, Japan.

Yuki Uchihara (Y)

Division of Molecular Oncological Pharmacy, Shibakoen, Minato-ku, Tokyo, Japan.

Yu Kato (Y)

Division of Molecular Oncological Pharmacy, Shibakoen, Minato-ku, Tokyo, Japan.

Atsushi Shibata (A)

Division of Molecular Oncological Pharmacy, Shibakoen, Minato-ku, Tokyo, Japan.

Classifications MeSH